Prostate-Specific Antigen Bounce after <sup>125</sup>I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer
Prostate-specific antigen (PSA) bounce is common in patients undergoing <sup>125</sup>I brachytherapy (BT), and our study investigated its clinical features. A total of 100 patients who underwent BT were analyzed. PSA bounce and large bounce were defined as an increase of ≥0.2 and ≥2.0 n...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/19/4907 |
| _version_ | 1797480120990040064 |
|---|---|
| author | Tae Hyung Kim Jason Joon Bock Lee Jaeho Cho |
| author_facet | Tae Hyung Kim Jason Joon Bock Lee Jaeho Cho |
| author_sort | Tae Hyung Kim |
| collection | DOAJ |
| description | Prostate-specific antigen (PSA) bounce is common in patients undergoing <sup>125</sup>I brachytherapy (BT), and our study investigated its clinical features. A total of 100 patients who underwent BT were analyzed. PSA bounce and large bounce were defined as an increase of ≥0.2 and ≥2.0 ng/mL above the initial PSA nadir, respectively, with a subsequent decline without treatment. Biochemical failure was defined using the Phoenix definition (nadir +2 ng/mL), except for a large bounce. With a median follow-up of 49 months, 45% and 7% of the patients experienced bounce and large bounce, respectively. The median time to bounce was 24 months, and the median PSA value at the bounce spike was 1.62 ng/mL, a median raise of 0.44 ng/mL compared to the pre-bounce nadir. The median time to bounce recovery was 4 months. The post-bounce nadir was obtained at a median of 36 months after low-dose-rate BT. On univariate analysis, age, the PSA nadir value at 2 years, and prostate volume were significant factors for PSA bounce. The PSA nadir value at 2 years remained significant in multivariate analysis. We should carefully monitor young patients with high prostate volume having a >0.5 PSA nadir value at 2 years for PSA bounce. |
| first_indexed | 2024-03-09T21:56:04Z |
| format | Article |
| id | doaj.art-c04a8d3e843a4039a50b00dbaa3f48e4 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T21:56:04Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c04a8d3e843a4039a50b00dbaa3f48e42023-11-23T19:58:38ZengMDPI AGCancers2072-66942022-10-011419490710.3390/cancers14194907Prostate-Specific Antigen Bounce after <sup>125</sup>I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate CancerTae Hyung Kim0Jason Joon Bock Lee1Jaeho Cho2Yonsei Cancer Center, Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, KoreaYonsei Cancer Center, Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, KoreaYonsei Cancer Center, Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, KoreaProstate-specific antigen (PSA) bounce is common in patients undergoing <sup>125</sup>I brachytherapy (BT), and our study investigated its clinical features. A total of 100 patients who underwent BT were analyzed. PSA bounce and large bounce were defined as an increase of ≥0.2 and ≥2.0 ng/mL above the initial PSA nadir, respectively, with a subsequent decline without treatment. Biochemical failure was defined using the Phoenix definition (nadir +2 ng/mL), except for a large bounce. With a median follow-up of 49 months, 45% and 7% of the patients experienced bounce and large bounce, respectively. The median time to bounce was 24 months, and the median PSA value at the bounce spike was 1.62 ng/mL, a median raise of 0.44 ng/mL compared to the pre-bounce nadir. The median time to bounce recovery was 4 months. The post-bounce nadir was obtained at a median of 36 months after low-dose-rate BT. On univariate analysis, age, the PSA nadir value at 2 years, and prostate volume were significant factors for PSA bounce. The PSA nadir value at 2 years remained significant in multivariate analysis. We should carefully monitor young patients with high prostate volume having a >0.5 PSA nadir value at 2 years for PSA bounce.https://www.mdpi.com/2072-6694/14/19/4907prostate cancerbrachytherapybounceprognostic factor |
| spellingShingle | Tae Hyung Kim Jason Joon Bock Lee Jaeho Cho Prostate-Specific Antigen Bounce after <sup>125</sup>I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer Cancers prostate cancer brachytherapy bounce prognostic factor |
| title | Prostate-Specific Antigen Bounce after <sup>125</sup>I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer |
| title_full | Prostate-Specific Antigen Bounce after <sup>125</sup>I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer |
| title_fullStr | Prostate-Specific Antigen Bounce after <sup>125</sup>I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer |
| title_full_unstemmed | Prostate-Specific Antigen Bounce after <sup>125</sup>I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer |
| title_short | Prostate-Specific Antigen Bounce after <sup>125</sup>I Brachytherapy Using Stranded Seeds with Intraoperative Optimization for Prostate Cancer |
| title_sort | prostate specific antigen bounce after sup 125 sup i brachytherapy using stranded seeds with intraoperative optimization for prostate cancer |
| topic | prostate cancer brachytherapy bounce prognostic factor |
| url | https://www.mdpi.com/2072-6694/14/19/4907 |
| work_keys_str_mv | AT taehyungkim prostatespecificantigenbounceaftersup125supibrachytherapyusingstrandedseedswithintraoperativeoptimizationforprostatecancer AT jasonjoonbocklee prostatespecificantigenbounceaftersup125supibrachytherapyusingstrandedseedswithintraoperativeoptimizationforprostatecancer AT jaehocho prostatespecificantigenbounceaftersup125supibrachytherapyusingstrandedseedswithintraoperativeoptimizationforprostatecancer |